Ataxia Telangiectasia; rare genetic disease; IEDAT; Erydel; pivotal ph

- iedat-project.eu

a pivotal phase III study will be conducted, and regulatory filing for market authorization of the therapy in EU and USA will be made by 2019.

Not Applicable $ 8.95